Global Search | Novartis

Hide Filters

Sort by

Relevance

Newest first

Oldest first

Showing 2663 results

Clinical Trials / Sep 25, 2024
A 24-week Study Evaluating the Effectiveness and Safety of Lucentis® 0.2mg in Retinopathy of Prematurity Participants in China
Clinical Trials / Oct 23, 2024
CAR-T Long Term Follow Up (LTFU) Study
Clinical Trials / Sep 19, 2024
Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
Clinical Trials / Oct 15, 2024
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
Clinical Trials / Mar 15, 2024
The Gilenya Pregnancy Registry
Clinical Trials / Jul 08, 2024
A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated With Zolgensma
Clinical Trials / Oct 10, 2024
Study of Out of Specification for Tisagenlecleucel
Clinical Trials / May 16, 2024
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
Key Release / Nov 21, 2024
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance upgraded to +6% CAGR 2023-2028 and +5% 2024-2029Strong momentum in the business with 8 in-market brands with USD 3bn+ to…
Event / Oct 07, 2024
Novartis Financial Results – Q2 2023
Novartis announced the company’s financial results for the second quarter and first half of 2023.

‹ Previous page
1
…
15
16
17
18
19
20
21
…
267
› Next page